Abstracts Archive - Page 1881 of 2425 - ACR Meeting Abstracts

Abstract Number: 2587 • 2014 ACR/ARHP Annual Meeting
Predictors of Treatment Response to Tumor Necrosis Factor-Alpha Blockers in Spondyloarthritis: Systematic Review and Meta-Analysis
Pauline Manicki¹, Jacques Morel², Bernard Combe³ and Cédric Lukas⁴, ¹immuno-rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ³Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁴Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France
Predictors of Treatment Response to Tumor Necrosis Factor-Alpha Blockers in Spondyloarthritis: Systematic Review and Meta-Analysis. Background/Purpose: TNF blockers have demonstrated substantial clinical efficacy in spondyloarthritis…
Abstract Number: 2586 • 2014 ACR/ARHP Annual Meeting
Which Characteristics of Inflammatory Back Pain (CBP) Forecast the Presence of Sacroiliitis on Magnetic Resonance Imaging (MRI)? Results from the Esperanza Cohort
Victoria Navarro-Compán¹, Raquel Almodóvar González², Azucena Hernández³, Emma Beltrán⁴, Eugenio De Miguel⁵, Robert B. M. Landewé⁶, Désirée van der Heijde⁷ and Pedro Zarco⁸, ¹Rheumatology, University Hospital La Paz and Leiden University Medical Center, Madrid, Spain, ²Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, ⁴University General Hospital of Valencia, Valencia, Spain, ⁵Rheumatology, University Hospital La Paz - IdiPaz, Madrid, Spain, ⁶Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Rheumatology Department, Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain
Background/Purpose: CBP is often the starting point for a suspicion of axSpA. In the ASAS-criteria for axial SpA either MRI of the SI-joints or HLA-B27-testing…
Abstract Number: 2585 • 2014 ACR/ARHP Annual Meeting
Association of Smoking with Acute Phase Reactants and Molecules Involved in Bone Formation in Patients with Ankylosing Spondylitis
Grigorios Sakellariou¹, Spyros Gerou², Dimitrios Oikonomou³ and Fares Sayegh⁴, ¹Rheumatology, 424 General Military Hospital, Thessaloniki, Greece, ²Laboratories "Analysis", Thessaloniki, Greece, ³Biopathology, 424 General Military Hospital, Thessaloniki, Greece, ⁴3rd Orthopaedic, "Papageorgiou" General Hospital, Thessaloniki, Greece
Background/Purpose: In patients with ankylosing spondylitis (AS), smoking is associated with increased disease activity and more radiographic damage. However, the mechanisms underlying the effects of…
Abstract Number: 2559 • 2014 ACR/ARHP Annual Meeting
Vitamin D insufficiency and Deficiency in Two European Cohorts of Patients with Inflammatory Rheumatic Disorders
Alessandra Vacca¹, Giovanni Porru¹, Grazia Dessole¹, Alessandro Mathieu¹, Catherine Cormier², Yvonne Fulla², Andre Kahan² and Yannick Allanore³, ¹Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ²Rheumatology A Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France, ³Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France
Background/Purpose Vitamin D plays an important role in the modulation of immune system and epidemiologic data indicate low vitamin D levels in autoimmune diseases such…
Abstract Number: 2558 • 2014 ACR/ARHP Annual Meeting
Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures
M.a.C. van der Weijden^1,2, J.C. van Denderen², W.F. Lems¹, M.T. Nurmohamed^1,2, B.a.C Dijkmans^1,2 and I.E. van der Horst-Bruinsma¹, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose Ankylosing spondylitis (AS) is characterized by chronic inflammation often leading to ankylosis of the spine, but also by a decrease of bone mineral density…
Abstract Number: 2557 • 2014 ACR/ARHP Annual Meeting
Are We over-Treating with Nsaids Our Early Axial Spa Patients? Results from the DESIR Cohort
Anna Moltó^1,2, Benjamin Granger³, Daniel Wendling⁴, Maxime Dougados⁵ and Laure Gossec⁶, ¹GRC-UPMC 08 (EEMOIS); UPMC Univ Paris 06.AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France., Paris, France, ²Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁵INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁶Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the keystone in the treatment of axial Spondyloarthritis (axSpA), and even in early forms, patients symptoms may lead to…
Abstract Number: 2556 • 2014 ACR/ARHP Annual Meeting
Is the Degree of NSAID Treatment in Early Axial Spondyloarthritis a Reflection of the physician’s Diagnosic Confidence? Results from the DESIR Cohort
Anna Moltó^1,2, Benjamin Granger³, Daniel Wendling⁴, Maxime Dougados⁵ and Laure Gossec⁶, ¹GRC-UPMC 08 (EEMOIS); UPMC Univ Paris 06.AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France., Paris, France, ²Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁵INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁶Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the keystone in the treatment of axial Spondyloarthritis (axSpA). Diagnosis is often not easy in early forms due to…
Abstract Number: 2555 • 2014 ACR/ARHP Annual Meeting
The Effect of Co-Medication with Conventional Synthetic (cs)Dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS)– Analysis from the Czech Biologics Registry Attra
Karel Pavelka¹, Jakub Zavada², Marketa Fojtikova³, Sarka Forejtova⁴ and Karel Hejduk⁵, ¹Institute of Rheumatology, Prague, Czech Republic, ²Charles University, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁴Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ⁵Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
Background/Purpose : The role of combined treatment with csDMARDs and anti-TNF therapy in AS is not well established. Methods: Main goal of this study was…
Abstract Number: 2554 • 2014 ACR/ARHP Annual Meeting
Do TNF Alpha Inhibitors Have an NSAID Sparing Effect in Real Life in Early Axial Spa? Results from the DESIR Cohort
Anna Moltó^1,2, Benjamin Granger³, Daniel Wendling⁴, Maxime A. Breban⁵, Maxime Dougados⁶ and Laure Gossec⁷, ¹GRC-UPMC 08 (EEMOIS); UPMC Univ Paris 06.AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France., Paris, France, ²Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP. INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ³Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁵Rheumatology, Ambroise Paré Hospital, and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁶INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁷Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are the keystone in the treatment of axial Spondyloarthritis (axSpA), but have potential side effects (cardiovascular and gastrointestinal). Effectiveness of…
Abstract Number: 2573 • 2014 ACR/ARHP Annual Meeting
Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index : A Best Worst Scaling
Uta Kiltz¹, Mickaël Hiligsmann², D van der Heijde³, Juergen Braun¹, Alarcos Cieza⁴, Walter P. Maksymowych⁵, William Taylor⁶ and Annelies Boonen⁷, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Psychology, University Southampton, Southampton, United Kingdom, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Department of Medicine, University of Otago Wellington, Wellington, New Zealand, ⁷Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose The ASAS Health Index (ASAS HI) is a disease-specific questionnaire aiming at measurement of health in patients with spondyloarthritis (SpA) which has been developed…
Abstract Number: 2572 • 2014 ACR/ARHP Annual Meeting
Recognition of Spondyloarthritis By General Practitioners in Daily Practice and the Effect of Education on This; A Study with Standardized Patients
Marloes van Onna¹, Simone Gorter², Bas Maiburg³, Gerrie Waagenaar³ and Astrid van Tubergen⁴, ¹Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, division of Rheumatology, Maastricht, Netherlands, ²Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of General Practice, Maastricht Univerisity, department of General Practice, Maastricht, Netherlands, ⁴Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Timely recognition and referral of patients with spondyloarthritis (SpA) is challenging due to the insidious disease onset and frequently unawareness of the clinical picture…
Abstract Number: 2571 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index
Inger Jorid Berg¹, Anne Grete Semb², Désirée van der Heijde^3,4, Tore K. Kvien⁴, Hanne Dagfinrud⁴, Jonny Hisdal^5,6 and Sella A. Provan², ¹Dep of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD), but the mediators of this increased risk are not known. Obesity is…
Abstract Number: 2570 • 2014 ACR/ARHP Annual Meeting
Validation of Modified Disease Activity and Functional Status Questionnaires in Spondyloarthritis
Itziar Quinzanos¹, Phat Luong¹, Sushmitha Bobba², J. Steuart Richards³, Vikas Majithia⁴, Lisa A. Davis⁵ and Liron Caplan⁶, ¹Rheumatology, Denver VA Medical Center, Denver, CO, ²Rheumatology/Research, Department of Veterans Affairs, Denver, CO, ³Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ⁴Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, ⁵Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, ⁶Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO
Background/Purpose Patients with new onset ankylosing spondylitis (AS) and those naïve to the Ankylosing Spondylitis Disease Activity Score (ASDAS) have voiced confusion over the use…
Abstract Number: 2569 • 2014 ACR/ARHP Annual Meeting
Profiles of Switches in Patient with Ankylosing Spondylitis: Comparing Adalimumab, Etanercept, Infliximab, Golimumab and Certolizumab
Jean-Pierre Raynauld¹, Louis Bessette², Denis Choquette¹, Isabelle Fortin³, Boulos Haraoui¹, Jean-Pierre Pelletier⁴, Marie-Anaïs Rémillard⁵, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: As much a 40% of patients with ankylosing spondylitis will fail (BASDAI≥ 4) different non-steroidal anti-inflammatory agents and will eventually be treated with an…
Abstract Number: 2568 • 2014 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data (RAPID3) Provides Similar Information Compared to Ankylosing Spondylitis Specific Indices: Analyses of the DESIR French Cohort
Isabel Castrejón¹, Theodore Pincus¹, Daniel Wendling² and Maxime Dougados³, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Service de Rhumatologie, CHU J Minjoz, Besancon, France, ³Université Paris René Descartes and Hôpital Cochin, Paris, France
Background/Purpose The Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI) –an index of only patient-self-report measures - has been the most widely used measure in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].